Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505826 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
A Phase 1 study, sponsored by Olema Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT04505826 is a Phase 1 study that has completed, run by Olema Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT04505826, a Phase 1 study, has completed, sponsored by Olema Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.
Interventions
- DRUG OP-1250
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04505826
The ClinicalTrials.gov registry entry for NCT04505826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olema Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OP-1250 is the first listed.
NCT04505826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04505826 about?
NCT04505826 is a clinical study titled "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer". This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.
What is the current status of trial NCT04505826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2020-08-13. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04505826?
The interventions under investigation include: OP-1250 (DRUG).
Who is sponsoring clinical trial NCT04505826?
This trial is sponsored by Olema Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.